

Oxitec Ltd
71 Innovation Drive
Milton Park
Abingdon
OX14 4RQ
United Kingdom
24 March 2020

Michael Mendelsohn
Chief, Emerging Technologies Branch
Biopesticides and Pollution Prevention Division
Office of Pesticide Programs
U.S. Environmental Protection Agency
Potomac Yard South
2777 Crystal Drive
Arlington, Virginia 22202
(703 463 7302)

## Authorization for Discussions with Florida Department of Agriculture and Consumer Services (FDACS)

Dear Mike,

Thank you and your team for your time yesterday. We appreciate the very helpful clarifications that were provided.

To follow up on the discussion of our next steps with the Florida Department of Agriculture and Consumer Services (FDACS), Oxitec authorizes BPPD to discuss with FDACS all aspects of our OX5034 EUP application (File Number 93167-EUP-E), whether claimed as CBI or not, with the exception of the following items:

| MRID Number | Title   |
|-------------|---|
| 50698701    | CONFIDENTIAL ATTACHMENT TO:   |
|             | OX5034 Aedes aegypti: Product Identity and Composition, Description of Starting Materials,      |
|             | Production and Formulation Process, Discussion of the Formation of Impurities, Preliminary      |
|             | Analysis, Certified Limits, and Enforcement Analytical Method                                   |
| 50698715    | CONFIDENTIAL ATTACHMENT TO:   |
| 50889415    | Dose Response of Hemizygous <i>Aedes aegypti</i> OX5034 to Tetracyclines and                    |
|             | Effects of Environmental Exposure to Tetracyclines  |
| 50698717    | CONFIDENTIAL ATTACHMENT TO:   |
| 50889417    | The self-limiting phenotype, penetrance, longevity and egg clutch size of Aedes aegypti, OX5034 |
| 50889423    | CONFIDENTIAL ATTACHMENT TO:   |
|             | Evaluation of Field Penetrance of OX5034 in Open Release Field Trials in Indaiatuba, São Paulo  |
|             | State, Brazil   |
| 50889424    | CONFIDENTIAL ATTACHMENT TO:   |
|             | OX5034 Aedes aegypti: Description of Starting Materials, Production and Formulation Process     |
| 50698723    | CONFIDENTIAL ATTACHMENT TO:   |
| 50889427    | Standard Operating Procedures for production of <i>Aedes aegypti</i> , OX5034                   |



| 50973402 | CONFIDENTIAL ATTACHMENT TO:   |
|----------|---|
|          | Tetracycline-Repressible Transactivator Protein Variant (tTAV-OX5034) and Related Genetic |
|          | Material from OX5034 Aedes aegypti:   |
|          | Modelling the Introgression of OX5034 Background Genetics                                 |
| N/A      | CONFIDENTIAL ATTACHMENT TO: Section G   |
|          | OX5034 Aedes aegypti: Proposed Field Trial Protocol for an Experimental Use Permit        |
| N/A      | Alternative CSF for Mosquito Eggs and Mosquito Rearing Box                                |

This authorization covers all individuals at FDACS who may be involved with the Oxitec Florida State EUP application, but does not extend to any other individuals. If individuals at FDACS request that BPPD provide them with actual documents that Oxitec has marked as CBI, we would request that you email such documents as password protected documents. If documents marked as exceptions in the table above need to be shared with FDACS, please contact Oxitec who will share these documents directly with FDACS.

Please do not hesitate to contact either me or Keith Matthews, should you have any questions.

Kind regards

Nathan Rose

Head of Regulatory Affairs

Oxitec Ltd

Cc: Keith A. Matthews, Wiley Rein LLP